Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gene Therapeutics & RNAi

PUBLISHER: Visiongain | PRODUCT CODE: 2099389

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 2099389

Global Cell & Gene Therapy Manufacturing Market Report 2026-2036

PUBLISHED:
PAGES: 509 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5959.50
PDF (Team License - Up to 6 Users)
USD 7055.50
PDF (Site License)
USD 8288.50
PDF (Enterprise License - Includes Free Datasets)
USD 10473.65

Add to Cart

Description

Table of Contents

List of Tables

Visiongain has published a new report, Cell & Gene Therapy Manufacturing Market Report 2026-2036, providing a comprehensive analysis of the global cell and gene therapy manufacturing market, including market size, growth drivers, competitive positioning, and revenue forecasts across therapy type, source of cells, scale of operation, type of manufacturer, and workflow segments.

The global cell and gene therapy manufacturing market is valued at US$13.7bn in 2026 and is forecast to reach US$63.0bn by 2036, at a CAGR of 16.5% over the forecast period.

This growth is driven by the expanding global clinical pipeline of cell and gene therapies, increasing commercial approvals, accelerating investment in dedicated manufacturing infrastructure, and advancing bioprocessing and automation technologies that are improving the scalability and commercial viability of advanced therapy production.

Access a Free Sample of This Report

Download a sample to explore:

  • Market forecasts and segment breakdowns
  • Competitive and company-level insights
  • Key trends shaping the market
  • Trade, policy, and supply chain analysis

Technological Innovation Driving Market Expansion

Advances in bioprocessing technologies and manufacturing automation are significantly improving the efficiency, consistency, and scalability of cell and gene therapy production. The increasing adoption of automated manufacturing systems, closed-process platforms, and real-time digital monitoring is reducing manual intervention, lowering contamination risk, and enhancing batch-to-batch consistency. These capabilities are particularly important for autologous cell therapies, where maintaining chain-of-identity and chain-of-custody throughout manufacturing is essential to product quality and patient safety.

In May 2026, Thermo Fisher Scientific introduced an integrated platform designed to enable more scalable and standardised cell therapy manufacturing, reflecting the industry's broader transition toward automated and digitally enabled production environments. The growing implementation of Process Analytical Technology (PAT) is further strengthening manufacturing performance by enabling continuous process monitoring, tighter process control, and earlier identification of production deviations.

Innovations in both upstream and downstream bioprocessing are improving production throughput, increasing facility utilisation, and supporting more efficient technology transfer across manufacturing sites. As these technologies mature, manufacturers are expected to achieve higher productivity, improved product consistency, and lower production costs across the value chain.

Trade, Policy & Supply Chain Dynamics

  • The cell and gene therapy manufacturing market is significantly affected by U.S. tariffs on imported bioprocessing equipment, single-use technologies, laboratory instruments, and cold-chain infrastructure.
  • The sector relies extensively on globally sourced raw materials including bioreactors, filtration assemblies, cryopreservation technologies, plasmid DNA, viral vectors, and analytical instruments, many of which are manufactured or assembled in tariff-affected regions, particularly China and other parts of Asia.
  • The financial impact has been most pronounced among emerging biotechnology companies and smaller CGT developers, which rely heavily on outsourced manufacturing and have less flexibility to absorb higher input costs.
  • Larger pharmaceutical companies have been better positioned to mitigate tariff pressures through diversified supplier networks, long-term procurement agreements, and greater purchasing power.
  • Trade-related pressures are accelerating a strategic shift toward regional manufacturing, with industry participants expanding capacity across North America and Europe, strengthening dual-source procurement for critical raw materials, and investing in closed-system and modular manufacturing platforms.

Commercial Impact

  • Cost pressure: Tariffs on bioprocessing equipment, laboratory instruments, and advanced manufacturing technologies are increasing procurement costs for therapy developers and CDMOs across the manufacturing value chain
  • Supply chain shifts: Manufacturers are accelerating regionalisation of production, strengthening dual-source procurement strategies, and investing in closed-system and modular facilities to reduce dependence on complex global supply chains
  • Manufacturing localisation: Leading CDMOs including Lonza and Catalent are expanding manufacturing capacity across North America and Europe in response to tariff dynamics and growing demand for regionally anchored production
  • Competitive positioning: Companies with diversified supply networks and established regional manufacturing footprints are better positioned to manage cost volatility and maintain programme delivery timelines

Company Intelligence

The cell and gene therapy manufacturing market is characterised by a mix of global CDMO leaders, specialist advanced therapy manufacturers, and large pharmaceutical companies competing across manufacturing capability, regulatory expertise, and technology platform breadth.

Leading companies including Lonza, Thermo Fisher Scientific, Catalent, Charles River Laboratories, and Fujifilm Diosynth Biotechnologies are strengthening their positions through capacity expansion, technology investment, and strategic partnerships across viral vector, cell therapy, and fill-finish manufacturing.

Competition is increasingly defined by:

  • End-to-end CDMO capability across process development, vector production, fill and finish, and analytical testing
  • Automation and closed-system manufacturing platform technology
  • Viral vector production capacity and technical expertise across AAV, lentiviral, and adenoviral applications
  • Ability to support both autologous and allogeneic manufacturing at clinical and commercial scale

This report analyses how competitive positioning is evolving across 16 leading companies, identifying where value is being created and how strategies are expected to shift over the forecast period.

Key Questions Answered

  • What is the projected size of the cell and gene therapy manufacturing market through 2036?
  • Which therapy types, workflows, and regions will drive growth?
  • How will advances in bioprocessing automation and allogeneic platforms reshape the manufacturing landscape?
  • What is the impact of U.S. trade tariffs on manufacturing costs and supply chain strategies?
  • Who are the leading companies and how will their positions evolve?

Report Scope and Data Coverage

  • Global cell and gene therapy manufacturing market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across therapy type, source of cells, scale of operation, type of manufacturer, and workflow
  • Regional and national market forecasts across five regions and 30+ leading national markets
  • Competitive intelligence on 16 leading companies

Includes both quantitative forecasting and qualitative strategic analysis, covering technology, competition, policy, and supply chain dynamics.

Segmentation Framework

By Therapy Type

  • Cell Therapy
  • Immune Cell Therapy (CAR-T, TCR-T, TIL, NK Cell Therapy, Dendritic Cell Therapy, Others)
  • Stem Cell Therapy (Hematopoietic Stem Cells, Mesenchymal Stromal Cells, iPSC-derived, ESC-derived, Others)
  • Gene Therapy
  • Viral Vector Gene Therapy (AAV, Lentiviral, Adenoviral, Retroviral, Other Viral Vectors)
  • Non-Viral Gene Therapy (Plasmid DNA, mRNA, Gene Editing Systems and Components, Oligonucleotide-Based Therapies)

By Source of Cells

  • Autologous Cells
  • Allogeneic Cells
  • Others

By Scale of Operation

  • Clinical Scale
  • Commercial Scale

By Type of Manufacturer

  • In-house Manufacturers
  • Contract Manufacturing Organisations

By Workflow

  • Process Development
  • Cell Processing
  • Vector Production
  • Fill & Finish Operations
  • Cell Banking
  • Analytical & Quality Testing
  • Raw Material Testing
  • Others

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Egypt
  • Rest of MEA

Company Intelligence Coverage

This report includes detailed profiles of 16 leading companies, including:

  • Boehringer Ingelheim International GmbH
  • Catalent, Inc. (Novo Holdings A/S)
  • Charles River Laboratories International, Inc.
  • Hoffmann-La Roche Ltd.
  • Fujifilm Biotechnologies (Fujifilm Holdings Corporation)
  • Genetix Biotherapeutics Inc.
  • Lonza
  • Merck KGaA
  • Miltenyi Biomedicine
  • Minaris Advanced Therapies, LLC
  • Novartis AG
  • Oxford Biomedica PLC
  • Resonac Corporation
  • Samsung Epis Holdings
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.

This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Policy and regulatory impact assessment
  • Supply chain and sourcing intelligence
  • Scenario modelling including tariffs and geopolitical risk

Why This Market Intelligence Matters

  • The cell and gene therapy manufacturing market is evolving rapidly, driven by pipeline maturation, increasing commercial approvals, and accelerating investment in manufacturing infrastructure and automation technologies.
  • Organisations that understand these dynamics will be better positioned to capture outsourcing opportunities, manage supply chain risk, and strengthen competitive positioning.
  • Purchase the Cell & Gene Therapy Manufacturing Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.
Show more
Product Code: PHA1392

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Cell & Gene Therapy Manufacturing Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Rising Clinical Pipeline and Commercial Approvals of Cell & Gene Therapies
      • 3.3.1.2 Increasing Investment in Manufacturing Infrastructure and Capacity Expansion
      • 3.3.1.3 Technological Advancements in Bioprocessing and Automation
      • 3.3.1.4 Growing Demand for Viral Vectors and Gene Editing Technologies
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 High Manufacturing Costs and Process Complexity
      • 3.3.2.2 Supply Chain and Raw Material Constraints
      • 3.3.2.3 Regulatory and Standardization Challenges
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Expansion of Allogeneic Therapies
      • 3.3.3.2 Growth of Contract Development and Manufacturing Organizations (CDMOs)
      • 3.3.3.3 Integration of Digital Manufacturing and AI-Driven Analytics
      • 3.3.3.4 Emerging Markets and Global Expansion
  • 3.4 U.S. Tariffs: What's the Impact on Global Cell & Gene Therapy Manufacturing Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
      • 3.4.2.1 Why V-Shaped Recovery?
      • 3.4.2.2 Impact from Tariffs
      • 3.4.2.3 Market Dynamics and Demand Recovery
      • 3.4.2.4 Policy and Funding Support
      • 3.4.2.5 Timeframe for Recovery
    • 3.4.3 U-Shaped Recovery Scenario
      • 3.4.3.1 Why U-Shaped Recovery?
      • 3.4.3.2 Impact from Tariffs
      • 3.4.3.3 Market Dynamics and Demand Recovery
      • 3.4.3.4 Policy and Funding Support
      • 3.4.3.5 Timeframe for Recovery
    • 3.4.4 L Shaped Recovery Scenario
      • 3.4.4.1 Why L-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
      • 3.4.4.5 Timeframe for Recovery
    • 3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2031) and Long-term (2026-2036) Planning?
    • 3.4.6 Impact of U.S. and China Trade War on Cell & Gene Therapy Manufacturing Market
    • 3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PESTLE Analysis

4 Cell & Gene Therapy Manufacturing Market Analysis by Therapy Type

  • 4.1 Key Findings
  • 4.2 Therapy Type Segment: Market Attractiveness Index
  • 4.3 Global Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Therapy Type
  • 4.4 Cell Therapy Manufacturing
    • 4.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)
    • 4.4.3 Global Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Cell Therapy Manufacturing
    • 4.4.4 Immune Cell Therapies
      • 4.4.4.1 Market Size by Region, 2026-2036 (US$ Million)
      • 4.4.4.2 Market Share by Region, 2026 & 2036 (%)
      • 4.4.4.3 Global Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Immune Cell Therapy
      • 4.4.4.4 CAR-T
        • 4.4.4.4.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.4.4.4.2 Market Share by Region, 2026 & 2036 (%)
      • 4.4.4.5 TCR-T
        • 4.4.4.5.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.4.4.5.2 Market Share by Region, 2026 & 2036 (%)
      • 4.4.4.6 TIL
        • 4.4.4.6.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.4.4.6.2 Market Share by Region, 2026 & 2036 (%)
      • 4.4.4.7 NK Cell Therapy
        • 4.4.4.7.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.4.4.7.2 Market Share by Region, 2026 & 2036 (%)
      • 4.4.4.8 Dendritic Cell Therapy
        • 4.4.4.8.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.4.4.8.2 Market Share by Region, 2026 & 2036 (%)
      • 4.4.4.9 Other Cells
        • 4.4.4.9.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.4.4.9.2 Market Share by Region, 2026 & 2036 (%)
    • 4.4.5 Stem Cell Therapies
      • 4.4.5.1 Market Size by Region, 2026-2036 (US$ Million)
      • 4.4.5.2 Market Share by Region, 2026 & 2036 (%)
      • 4.4.5.3 Global Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Stem Cell Therapy
      • 4.4.5.4 Hematopoietic Stem Cells (HSC)
        • 4.4.5.4.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.4.5.4.2 Market Share by Region, 2026 & 2036 (%)
      • 4.4.5.5 Mesenchymal Stromal Cells (MSC)
        • 4.4.5.5.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.4.5.5.2 Market Share by Region, 2026 & 2036 (%)
      • 4.4.5.6 iPSC-Derived Cell Therapies
        • 4.4.5.6.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.4.5.6.2 Market Share by Region, 2026 & 2036 (%)
      • 4.4.5.7 ESC-Derived Cell Therapies
        • 4.4.5.7.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.4.5.7.2 Market Share by Region, 2026 & 2036 (%)
    • 4.4.6 Other Somatic Cell Therapy
      • 4.4.6.1 Market Size by Region, 2026-2036 (US$ Million)
      • 4.4.6.2 Market Share by Region, 2026 & 2036 (%)
  • 4.5 Gene Therapy Manufacturing
    • 4.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.5.2 Market Share by Region, 2026 & 2036 (%)
    • 4.5.3 Global Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Gene Therapy Manufacturing
    • 4.5.4 Viral Vector Gene Therapy
      • 4.5.4.1 Market Size by Region, 2026-2036 (US$ Million)
      • 4.5.4.2 Market Share by Region, 2026 & 2036 (%)
      • 4.5.4.3 Global Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Viral Vector Gene Therapy
      • 4.5.4.4 AAV
        • 4.5.4.4.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.5.4.4.2 Market Share by Region, 2026 & 2036 (%)
      • 4.5.4.5 Lentiviral
        • 4.5.4.5.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.5.4.5.2 Market Share by Region, 2026 & 2036 (%)
      • 4.5.4.6 Adenoviral
        • 4.5.4.6.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.5.4.6.2 Market Share by Region, 2026 & 2036 (%)
      • 4.5.4.7 Retroviral
        • 4.5.4.7.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.5.4.7.2 Market Share by Region, 2026 & 2036 (%)
      • 4.5.4.8 Other Viral Vectors
        • 4.5.4.8.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.5.4.8.2 Market Share by Region, 2026 & 2036 (%)
    • 4.5.5 Non-Viral Gene Therapy
      • 4.5.5.1 Market Size by Region, 2026-2036 (US$ Million)
      • 4.5.5.2 Market Share by Region, 2026 & 2036 (%)
      • 4.5.5.3 Global Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Non-Viral Gene Therapy
      • 4.5.5.4 Plasmid DNA
        • 4.5.5.4.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.5.5.4.2 Market Share by Region, 2026 & 2036 (%)
      • 4.5.5.5 mRNA
        • 4.5.5.5.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.5.5.5.2 Market Share by Region, 2026 & 2036 (%)
      • 4.5.5.6 Gene Editing Systems & Components
        • 4.5.5.6.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.5.5.6.2 Market Share by Region, 2026 & 2036 (%)
      • 4.5.5.7 Oligonucleotide Based Therapies
        • 4.5.5.7.1 Market Size by Region, 2026-2036 (US$ Million)
        • 4.5.5.7.2 Market Share by Region, 2026 & 2036 (%)

5 Cell & Gene Therapy Manufacturing Market Analysis by Source of Cells

  • 5.1 Key Findings
  • 5.2 Source of Cells Segment: Market Attractiveness Index
  • 5.3 Global Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Source of Cells
  • 5.4 Autologous Cells
    • 5.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 Allogeneic Cells
    • 5.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)
  • 5.6 Others
    • 5.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.6.2 Market Share by Region, 2026 & 2036 (%)

6 Cell & Gene Therapy Manufacturing Market Analysis by Scale of Operation

  • 6.1 Key Findings
  • 6.2 Scale of Operation Segment: Market Attractiveness Index
  • 6.3 Global Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 6.4 Clinical Scale
    • 6.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Commercial Scale
    • 6.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)

7 Cell & Gene Therapy Manufacturing Market Analysis by Type of Manufacturer

  • 7.1 Key Findings
  • 7.2 Type of Manufacturer Segment: Market Attractiveness Index
  • 7.3 Global Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Type of Manufacturer
  • 7.4 In-house Manufacturers
    • 7.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)
  • 7.5 Contract Manufacturing Organizations
    • 7.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.5.2 Market Share by Region, 2026 & 2036 (%)

8 Cell & Gene Therapy Manufacturing Market Analysis by Workflow

  • 8.1 Key Findings
  • 8.2 Workflow Segment: Market Attractiveness Index
  • 8.3 Global Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Workflow
  • 8.4 Process Development
    • 8.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.4.2 Market Share by Region, 2026 & 2036 (%)
  • 8.5 Cell Processing
    • 8.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.5.2 Market Share by Region, 2026 & 2036 (%)
  • 8.6 Vector Production
    • 8.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.6.2 Market Share by Region, 2026 & 2036 (%)
  • 8.7 Fill & Finish Operations
    • 8.7.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.7.2 Source: Visiongain, 2026
    • 8.7.3 Market Share by Region, 2026 & 2036 (%)
  • 8.8 Cell Banking
    • 8.8.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.8.2 Market Share by Region, 2026 & 2036 (%)
  • 8.9 Analytical & Quality Testing
    • 8.9.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.9.2 Market Share by Region, 2026 & 2036 (%)
  • 8.10 Raw Material Testing
    • 8.10.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.10.2 Market Share by Region, 2026 & 2036 (%)
  • 8.11 Others
    • 8.11.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.11.2 Market Share by Region, 2026 & 2036 (%)

9 Cell & Gene Therapy Manufacturing Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America Cell & Gene Therapy Manufacturing Market Analysis

  • 10.1 Key Findings
  • 10.2 North America Cell & Gene Therapy Manufacturing Market Attractiveness Index
  • 10.3 North America Cell & Gene Therapy Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 10.4 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Country
  • 10.5 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Therapy Type
  • 10.6 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Cell Therapy Manufacturing
    • 10.6.1 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Immune Cell Therapies
    • 10.6.2 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Stem Cell Therapies
  • 10.7 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Gene Therapy Manufacturing
    • 10.7.1 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Viral Vector Gene Therapy
    • 10.7.2 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Non-Viral Gene Therapy
  • 10.8 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Source of Cells
  • 10.9 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 10.10 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Type of Manufacturer
  • 10.11 North America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Workflow
  • 10.12 U.S. Cell & Gene Therapy Manufacturing Market Analysis
  • 10.13 Canada Cell & Gene Therapy Manufacturing Market Analysis

11 Europe Cell & Gene Therapy Manufacturing Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe Cell & Gene Therapy Manufacturing Market Attractiveness Index
  • 11.3 Europe Cell & Gene Therapy Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 11.4 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Country
  • 11.5 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Therapy Type
  • 11.6 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Cell Therapy Manufacturing
    • 11.6.1 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Immune Cell Therapies
    • 11.6.2 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Stem Cell Therapies
  • 11.7 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Gene Therapy Manufacturing
    • 11.7.1 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Viral Vector Gene Therapy
    • 11.7.2 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Non-Viral Gene Therapy
  • 11.8 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Source of Cells
  • 11.9 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 11.10 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Type of Manufacturer
  • 11.11 Europe Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Workflow
  • 11.12 Germany Cell & Gene Therapy Manufacturing Market Analysis
  • 11.13 UK Cell & Gene Therapy Manufacturing Market Analysis
  • 11.14 France Cell & Gene Therapy Manufacturing Market Analysis
  • 11.15 Italy Cell & Gene Therapy Manufacturing Market Analysis
  • 11.16 Spain Cell & Gene Therapy Manufacturing Market Analysis
  • 11.17 Russia Cell & Gene Therapy Manufacturing Market Analysis
  • 11.18 Rest of Europe Cell & Gene Therapy Manufacturing Market Analysis

12 Asia Pacific Cell & Gene Therapy Manufacturing Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific Cell & Gene Therapy Manufacturing Market Attractiveness Index
  • 12.3 Asia Pacific Cell & Gene Therapy Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 12.4 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Country
  • 12.5 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Therapy Type
  • 12.6 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Cell Therapy Manufacturing
    • 12.6.1 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Immune Cell Therapies
    • 12.6.2 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Stem Cell Therapies
  • 12.7 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Gene Therapy Manufacturing
    • 12.7.1 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Viral Vector Gene Therapy
    • 12.7.2 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Non-Viral Gene Therapy
  • 12.8 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Source of Cells
  • 12.9 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 12.10 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Type of Manufacturer
  • 12.11 Asia Pacific Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Workflow
  • 12.12 Japan Cell & Gene Therapy Manufacturing Market Analysis
  • 12.13 China Cell & Gene Therapy Manufacturing Market Analysis
  • 12.14 India Cell & Gene Therapy Manufacturing Market Analysis
  • 12.15 Australia Cell & Gene Therapy Manufacturing Market Analysis
  • 12.16 South Korea Cell & Gene Therapy Manufacturing Market Analysis
  • 12.17 Rest of Asia Pacific Cell & Gene Therapy Manufacturing Market Analysis

13 Latin America Cell & Gene Therapy Manufacturing Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Cell & Gene Therapy Manufacturing Market Attractiveness Index
  • 13.3 Latin America Cell & Gene Therapy Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 13.4 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Country
  • 13.5 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Therapy Type
  • 13.6 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Cell Therapy Manufacturing
    • 13.6.1 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Immune Cell Therapies
    • 13.6.2 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Stem Cell Therapies
  • 13.7 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Gene Therapy Manufacturing
    • 13.7.1 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Viral Vector Gene Therapy
    • 13.7.2 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Non-Viral Gene Therapy
  • 13.8 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Source of Cells
  • 13.9 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 13.10 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Type of Manufacturer
  • 13.11 Latin America Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Workflow
  • 13.12 Brazil Cell & Gene Therapy Manufacturing Market Analysis
  • 13.13 Mexico Cell & Gene Therapy Manufacturing Market Analysis
  • 13.14 Argentina Cell & Gene Therapy Manufacturing Market Analysis
  • 13.15 Rest of Latin America Cell & Gene Therapy Manufacturing Market Analysis

14 MEA Cell & Gene Therapy Manufacturing Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA Cell & Gene Therapy Manufacturing Market Attractiveness Index
  • 14.3 MEA Cell & Gene Therapy Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 14.4 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Country
  • 14.5 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Therapy Type
  • 14.6 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Cell Therapy Manufacturing
    • 14.6.1 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Immune Cell Therapies
    • 14.6.2 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Stem Cell Therapies
  • 14.7 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Gene Therapy Manufacturing
    • 14.7.1 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Viral Vector Gene Therapy
    • 14.7.2 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Non-Viral Gene Therapy
  • 14.8 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Source of Cells
  • 14.9 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Scale of Operation
  • 14.10 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Type of Manufacturer
  • 14.11 MEA Cell & Gene Therapy Manufacturing Market Size Estimation and Forecast by Workflow
  • 14.12 GCC Cell & Gene Therapy Manufacturing Market Analysis
  • 14.13 South Africa Cell & Gene Therapy Manufacturing Market Analysis
  • 14.14 Egypt Cell & Gene Therapy Manufacturing Market Analysis
  • 14.15 Rest of MEA Cell & Gene Therapy Manufacturing Market Analysis

15 Company Profiles

  • 15.1 Competitive Landscape, 2025
  • 15.2 Strategic Outlook
  • 15.3 Genetix Biotherapeutics Inc.
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Product Benchmarking
    • 15.3.4 Strategic Outlook
  • 15.4 Boehringer Ingelheim International GmbH
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2021-2025
      • 15.4.3.2 R&D, 2021-2025
      • 15.4.3.3 Regional Market Shares, 2025
      • 15.4.3.4 Business Segment Market Shares, 2025
    • 15.4.4 Product Benchmarking
    • 15.4.5 Strategic Outlook
  • 15.5 Catalent, Inc. (Novo Holdings A/S)
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2021-2025
    • 15.5.4 Product Benchmarking
    • 15.5.5 Strategic Outlook
  • 15.6 Charles River Laboratories International
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2021-2025
      • 15.6.3.2 Regional Market Shares, 2025
      • 15.6.3.3 Business Segment Market Shares, 2025
    • 15.6.4 Product Benchmarking
    • 15.6.5 Strategic Outlook
  • 15.7 F. Hoffmann-La Roche Ltd.
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2021-2025
      • 15.7.3.2 R&D, 2021-2025
      • 15.7.3.3 Regional Market Shares, 2025
      • 15.7.3.4 Business Segment Market Shares, 2025
    • 15.7.4 Product Benchmarking
    • 15.7.5 Strategic Outlook
  • 15.8 Fujifilm Biotechnologies (Fujifilm Holdings Corporation)
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2021-2025
      • 15.8.3.2 R&D, 2021-2025
      • 15.8.3.3 Regional Market Shares, 2025
      • 15.8.3.4 Business Segment Market Shares, 2025
    • 15.8.4 Product Benchmarking
    • 15.8.5 Strategic Outlook
  • 15.9 Lonza
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Financial Analysis
      • 15.9.3.1 Net Revenue, 2021-2025
      • 15.9.3.2 R&D, 2021-2025
      • 15.9.3.3 Regional Market Shares, 2025
      • 15.9.3.4 Business Segment Market Shares, 2025
    • 15.9.4 Product Benchmarking
    • 15.9.5 Strategic Outlook
  • 15.10 Merck KGaA
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2021-2025
      • 15.10.3.2 R&D, 2021-2025
      • 15.10.3.3 Regional Market Shares, 2025
      • 15.10.3.4 Business Segment Market Shares, 2025
    • 15.10.4 Product Benchmarking
    • 15.10.5 Strategic Outlook
  • 15.11 Miltenyi Biomedicine
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Product Benchmarking
    • 15.11.4 Strategic Outlook
  • 15.12 Novartis AG
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Financial Analysis
      • 15.12.3.1 Net Revenue, 2021-2025
      • 15.12.3.2 R&D, 2021-2025
      • 15.12.3.3 Regional Market Shares, 2025
      • 15.12.3.4 Business Segment Market Shares, 2025
    • 15.12.4 Product Benchmarking
    • 15.12.5 Strategic Outlook
  • 15.13 OxFord Biomedica PLC
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Financial Analysis
      • 15.13.3.1 Net Revenue, 2021-2025
      • 15.13.3.2 R&D, 2021-2025
      • 15.13.3.3 Regional Market Shares, 2025
      • 15.13.3.4 Business Segment Market Shares, 2025
    • 15.13.4 Product Benchmarking
    • 15.13.5 Strategic Outlook
  • 15.14 Resonac Corporation
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Financial Analysis
      • 15.14.3.1 Net Revenue, 2021-2025
      • 15.14.3.2 Business Segment Market Shares, 2025
    • 15.14.4 Product Benchmarking
  • 15.15 Samsung Epis Holdings
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Financial Analysis
      • 15.15.3.1 Net Revenue, 2021-2025
    • 15.15.4 Product Benchmarking
    • 15.15.5 Strategic Outlook
  • 15.16 Takara Bio, Inc.
    • 15.16.1 Company Snapshot
    • 15.16.2 Company Overview
    • 15.16.3 Financial Analysis
      • 15.16.3.1 Net Revenue, 2021-2025
      • 15.16.3.2 R&D, 2021-2025
      • 15.16.3.3 Business Segment Market Shares, 2025
    • 15.16.4 Product Benchmarking
    • 15.16.5 Strategic Outlook
  • 15.17 Thermo Fisher Scientific
    • 15.17.1 Company Snapshot
    • 15.17.2 Company Overview
    • 15.17.3 Financial Analysis
      • 15.17.3.1 Net Revenue, 2021-2025
      • 15.17.3.2 R&D, 2021-2025
      • 15.17.3.3 Regional Market Shares, 2025
      • 15.17.3.4 Business Segment Market Shares, 2025
    • 15.17.4 Product Benchmarking
    • 15.17.5 Strategic Outlook
  • 15.18 Minaris Advanced Therapies, LLC
    • 15.18.1 Company Snapshot
    • 15.18.2 Company Overview
    • 15.18.3 Product Benchmarking
    • 15.18.4 Strategic Outlook

16 Conclusion & Recommendation

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendation
Show more
Product Code: PHA1392

List of Tables

  • Table 1 Cell & Gene Therapy Manufacturing Market Snapshot, 2026 & 2036 (US$ Million, CAGR %)
  • Table 2 Cell & Gene Therapy Manufacturing Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: V- Shaped Recovery Scenario
  • Table 3 Cell & Gene Therapy Manufacturing Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
  • Table 4 Cell & Gene Therapy Manufacturing Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
  • Table 5 Cell & Gene Therapy Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 6 Cell Therapy Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 7 Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 8 Immune Cell Therapy Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 9 Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 10 CAR-T Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 11 TCR-T Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 12 TIL Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 13 NK Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 14 Dendritic Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 15 Other Cells Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 16 Stem Cell Therapies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 17 Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 18 Hematopoietic Stem Cells (HSC) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 19 Mesenchymal Stromal Cells (MSC) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 20 iPSC-Derived Cell Therapies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 21 ESC-Derived Cell Therapies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 22 Other Somatic Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 23 Gene Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 24 Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 25 Viral Vector Gene Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 26 Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 27 AAV Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 28 Lentiviral Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 29 Adenoviral Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 30 Retroviral Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 31 Other Viral Vectors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 32 Non-Viral Gene Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 33 Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 34 Plasmid DNA Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 35 mRNA Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 36 Gene Editing Systems & Components Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 37 Oligonucleotide Based Therapies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 38 Cell & Gene Therapy Manufacturing Market Forecast by Source of Cells, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 39 Autologous Cells Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 40 Allogeneic Cells Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 41 Other Cells Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 42 Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 43 Clinical Scale Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 44 Commercial Scale Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 45 Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 46 In-house Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 47 Contract Manufacturing Organizations Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 48 Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 49 Process Development Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 50 Cell Processing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 51 Vector Production Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 52 Fill & Finish Operations Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 53 Cell Banking Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 54 Analytical & Quality Testing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 55 Raw Material Testing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 56 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 57 Cell & Gene Therapy Manufacturing Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 58 North America Cell & Gene Therapy Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 59 North America Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 60 North America Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 61 North America Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapies, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 62 North America Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapies, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 63 North America Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 64 North America Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 65 North America Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 66 North America Cell & Gene Therapy Manufacturing Market Forecast by Sources of Cells, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 67 North America Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operations, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 68 North America Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 69 North America Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 70 U.S. Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 71 Canada Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 72 Europe Cell & Gene Therapy Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 73 Europe Cell & Gene Therapy Manufacturing Market Forecast by Therapy Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 74 Europe Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 75 Europe Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapies, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 76 Europe Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapies, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 77 Europe Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 78 Europe Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 79 Europe Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 80 Europe Cell & Gene Therapy Manufacturing Market Forecast by Sources of Cells, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 81 Europe Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operations, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 82 Europe Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 83 Europe Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 84 Germany Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 85 UK Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 86 France Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 87 Italy Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 88 Spain Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 89 Russia Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 90 Rest of Europe Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 91 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 92 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Therapy Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 93 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 94 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapies, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 95 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapies, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 96 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 97 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 98 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 99 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Sources of Cells, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 100 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operations, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 101 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 102 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 103 Japan Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 104 China Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 105 India Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 106 Australia Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 107 South Korea Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 108 Rest of Asia Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 109 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 110 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Therapy Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 111 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 112 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapies, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 113 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapies, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 114 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 115 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 116 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 117 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Sources of Cells, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 118 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operations, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 119 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 120 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 121 Brazil Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 122 Mexico Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 123 Argentina Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 124 Rest of Latin America Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 125 MEA Cell & Gene Therapy Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 126 MEA Cell & Gene Therapy Manufacturing Market Forecast by Therapy Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 127 MEA Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 128 MEA Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapies, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 129 MEA Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapies, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 130 MEA Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 131 MEA Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 132 MEA Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 133 MEA Cell & Gene Therapy Manufacturing Market Forecast by Sources of Cells, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 134 MEA Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operations, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 135 MEA Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 136 MEA Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 137 GCC Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 138 South Africa Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 139 Egypt Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 140 Rest of MEA Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 141 Strategic Outlook
  • Table 142 Genetix Biotherapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 143 Genetix Biotherapeutics Inc.: Product Benchmarking
  • Table 144 Genetix Biotherapeutics Inc.: Strategic Outlook
  • Table 145 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 146 Boehringer Ingelheim International GmbH: Product Benchmarking
  • Table 147 Boehringer Ingelheim International GmbH: Strategic Outlook
  • Table 148 Catalent, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 149 Catalent, Inc.: Product Benchmarking
  • Table 150 Catalent, Inc.: Strategic Outlook
  • Table 151 Charles River Laboratories International Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 152 Charles River Laboratories International Inc.: Product Benchmarking
  • Table 153 Charles River Laboratories International Inc.: Strategic Outlook
  • Table 154 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 155 F. Hoffmann-La Roche Ltd.: Product Benchmarking
  • Table 156 F. Hoffmann-La Roche Ltd.: Strategic Outlook
  • Table 157 Fujifilm Biotechnologies (Fujifilm Holdings Corporation): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 158 Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation): Product Benchmarking
  • Table 159 Fujifilm Diosynth Biotechnologies (Fujifilm Holdings Corporation): Strategic Outlook
  • Table 160 Lonza: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 161 Lonza: Product Benchmarking
  • Table 162 Lonza: Strategic Outlook
  • Table 163 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 164 Merck KGaA: Product Benchmarking
  • Table 165 Merck KGaA: Strategic Outlook
  • Table 166 Miltenyi Biomedicine: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 167 Miltenyi Biomedicine: Product Benchmarking
  • Table 168 Miltenyi Biomedicine: Strategic Outlook
  • Table 169 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 170 Novartis AG: Product Benchmarking
  • Table 171 Novartis AG: Strategic Outlook
  • Table 172 OxFord Biomedica PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 173 OxFord Biomedica PLC: Product Benchmarking
  • Table 174 OxFord Biomedica PLC: Strategic Outlook
  • Table 175 Resonac Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 176 Resonac Corporation: Product Benchmarking
  • Table 177 Samsung Epis Holdings: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 178 Samsung Epis Holdings: Product Benchmarking
  • Table 179 Samsung Epis Holdings: Strategic Outlook
  • Table 180 Takara Bio, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 181 Takara Bio, Inc.: Product Benchmarking
  • Table 182 Takara Bio, Inc.: Strategic Outlook
  • Table 183 Thermo Fisher Scientific: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 184 Thermo Fisher Scientific: Product Benchmarking
  • Table 185 Thermo Fisher Scientific: Strategic Outlook
  • Table 186 Minaris Advanced Therapies, LLC ic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 187 Minaris Advanced Therapies, LLC: Product Benchmarking
  • Table 188 Minaris Advanced Therapies, LLC: Strategic Outlook

List of Figures

  • Figure 1 Cell & Gene Therapy Manufacturing Market Segmentation
  • Figure 2 Pharma Contract Sales Logistics Market Attractiveness Index by Therapy Type
  • Figure 3 Pharma Contract Sales Logistics Market Attractiveness Index by Source of Cells
  • Figure 4 Pharma Contract Sales Logistics Market Attractiveness Index by Scale Of Operation
  • Figure 5 Pharma Contract Sales Logistics Market Attractiveness Index by Type of Manufacturer
  • Figure 6 Pharma Contract Sales Logistics Market Attractiveness Index by Region
  • Figure 7 Cell & Gene Therapy Manufacturing Market: Market Dynamics
  • Figure 8 Cell & Gene Therapy Manufacturing Market: Impact Analysis
  • Figure 9 Cell & Gene Therapy Manufacturing Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 10 Cell & Gene Therapy Manufacturing Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 11 Cell & Gene Therapy Manufacturing Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 12 Short Term & Long-Term Planning
  • Figure 13 Impact of U.S. and China Trade War
  • Figure 14 Most Impacted Countries
  • Figure 15 Cell & Gene Therapy Manufacturing Market: Porter's Five Forces Analysis
  • Figure 16 Cell & Gene Therapy Manufacturing Market: PESTLE Analysis
  • Figure 17 Cell & Gene Therapy Manufacturing Market by Therapy Type: Market Attractiveness Index
  • Figure 18 Cell & Gene Therapy Manufacturing Market Forecast by Therapy Type, 2026-2036 (US$ Million, AGR %)
  • Figure 19 Cell & Gene Therapy Manufacturing Market Share Forecast by Therapy Type, 2026, 2031, 2036 (%)
  • Figure 20 Cell Therapy Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 21 Cell Therapy Manufacturing Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 22 Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 23 Cell & Gene Therapy Manufacturing Market Share Forecast by Cell Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 24 Immune Cell Therapies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 25 Immune Cell Therapies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 26 Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 27 Cell & Gene Therapy Manufacturing Market Share Forecast by Immune Cell Therapy, 2026, 2031, 2036 (%)
  • Figure 28 CAR-T Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 29 CAR-T Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 30 TCR-T Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 31 TCR-T Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 32 TIL Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 33 TIL Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 34 NK Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 35 NK Cell Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 36 Dendritic Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 37 Dendritic Cell Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 38 Other Cells Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 39 Other Cells Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 40 Stem Cell Therapies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 41 Stem Cell Therapies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 42 Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 43 Cell & Gene Therapy Manufacturing Market Share Forecast by Stem Cell Therapy, 2026, 2031, 2036 (%)
  • Figure 44 Hematopoietic Stem Cells (HSC) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 45 Hematopoietic Stem Cells (HSC) Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 46 Mesenchymal Stromal Cells (MSC) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 47 Mesenchymal Stromal Cells (MSC) Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 48 iPSC-Derived Cell Therapies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 49 iPSC-Derived Cell Therapies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 50 ESC-Derived Cell Therapies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 51 ESC-Derived Cell Therapies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 52 Other Somatic Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 53 Other Somatic Cell Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 54 Gene Therapy Manufacturing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 55 Gene Therapy Manufacturing Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 56 Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 57 Cell & Gene Therapy Manufacturing Market Share Forecast by Gene Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 58 Viral Vector Gene Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 59 Viral Vector Gene Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 60 Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 61 Cell & Gene Therapy Manufacturing Market Share Forecast by Viral Vector Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 62 AAV Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 63 AAV Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 64 Lentiviral Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 65 Lentiviral Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 66 Adenoviral Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 67 Adenoviral Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 68 Retroviral Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 69 Retroviral Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 70 Other Viral Vectors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 71 Other Viral Vectors Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 72 Non-Viral Gene Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 73 Non-Viral Gene Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 74 Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 75 Cell & Gene Therapy Manufacturing Market Share Forecast by Non-Viral Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 76 Plasmid DNA Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 77 Plasmid DNA Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 78 mRNA Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 79 mRNA Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 80 Gene Editing Systems & Components Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 81 Gene Editing Systems & Components Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 82 Oligonucleotide Based Therapies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 83 Oligonucleotide Based Therapies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 84 Cell & Gene Therapy Manufacturing Market by Source of Cells: Market Attractiveness Index
  • Figure 85 Cell & Gene Therapy Manufacturing Market Forecast by Source of Cells, 2026-2036 (US$ Million, AGR %)
  • Figure 86 Cell & Gene Therapy Manufacturing Market Share Forecast by Source of Cells, 2026, 2031, 2036 (%)
  • Figure 87 Autologous Cells Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 88 Autologous Cells Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 89 Allogeneic Cells Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 90 Allogeneic Cells Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 91 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 92 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 93 Cell & Gene Therapy Manufacturing Market by Scale of Operation: Market Attractiveness Index
  • Figure 94 Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 95 Cell & Gene Therapy Manufacturing Market Share Forecast by Scale of Operation, 2026, 2031, 2036 (%)
  • Figure 96 Clinical Scale Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 97 Clinical Scale Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 98 Commercial Scale Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 99 Commercial Scale Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 100 Cell & Gene Therapy Manufacturing Market by Type of Manufacturer: Market Attractiveness Index
  • Figure 101 Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR %)
  • Figure 102 Cell & Gene Therapy Manufacturing Market Share Forecast by Type of Manufacturer, 2026, 2031, 2036 (%)
  • Figure 103 In-house Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 104 In-house Manufacturers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 105 Contract Manufacturing Organizations Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 106 Contract Manufacturing Organizations Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 107 Cell & Gene Therapy Manufacturing Market by Workflow: Market Attractiveness Index
  • Figure 108 Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR %)
  • Figure 109 Cell & Gene Therapy Manufacturing Market Share Forecast by Workflow, 2026, 2031, 2036 (%)
  • Figure 110 Process Development Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 111 Process Development Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 112 Cell Processing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 113 Cell Processing Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 114 Vector Production Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 115 Vector Production Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 116 Fill & Finish Operations Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 117 Fill & Finish Operations Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 118 Cell Banking Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 119 Cell Banking Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 120 Analytical & Quality Testing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 121 Analytical & Quality Testing Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 122 Raw Material Testing Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 123 Raw Material Testing Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 124 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 125 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 126 Cell & Gene Therapy Manufacturing Market Forecast by Region 2026 and 2036 (Revenue, CAGR%)
  • Figure 127 Cell & Gene Therapy Manufacturing Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 128 Cell & Gene Therapy Manufacturing Market by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 129 North America Cell & Gene Therapy Manufacturing Market Attractiveness Index
  • Figure 130 North America Cell & Gene Therapy Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • Figure 131 North America Cell & Gene Therapy Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 132 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 133 North America Cell & Gene Therapy Manufacturing Market Forecast by Therapy Type, 2026-2036 (US$ Million, AGR %)
  • Figure 134 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Therapy Type, 2026, 2031, 2036 (%)
  • Figure 135 North America Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 136 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Cell Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 137 North America Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapies, 2026-2036 (US$ Million, AGR %)
  • Figure 138 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Immune Cell Therapies, 2026, 2031, 2036 (%)
  • Figure 139 North America Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapies, 2026-2036 (US$ Million, AGR %)
  • Figure 140 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Stem Cell Therapies, 2026, 2031, 2036 (%)
  • Figure 141 North America Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 142 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Gene Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 143 North America Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 144 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Viral Vector Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 145 North America Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 146 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Non-Viral Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 147 North America Cell & Gene Therapy Manufacturing Market Forecast by Source of Cells, 2026-2036 (US$ Million, AGR %)
  • Figure 148 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Source of Cells, 2026, 2031, 2036 (%)
  • Figure 149 North America Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 150 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Scale of Operation, 2026, 2031, 2036 (%)
  • Figure 151 North America Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR %)
  • Figure 152 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Type of Manufacturer, 2026, 2031, 2036 (%)
  • Figure 153 North America Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR %)
  • Figure 154 North America Cell & Gene Therapy Manufacturing Market Share Forecast by Workflow, 2026, 2031, 2036 (%)
  • Figure 155 U.S. Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 156 Canada Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 157 Europe Cell & Gene Therapy Manufacturing Market Attractiveness Index
  • Figure 158 Europe Cell & Gene Therapy Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • Figure 159 Europe Cell & Gene Therapy Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 160 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 161 Europe Cell & Gene Therapy Manufacturing Market Forecast by Therapy Type, 2026-2036 (US$ Million, AGR %)
  • Figure 162 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Therapy Type, 2026, 2031, 2036 (%)
  • Figure 163 Europe Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 164 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Cell Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 165 Europe Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapies, 2026-2036 (US$ Million, AGR %)
  • Figure 166 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Immune Cell Therapies, 2026, 2031, 2036 (%)
  • Figure 167 Europe Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapies, 2026-2036 (US$ Million, AGR %)
  • Figure 168 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Stem Cell Therapies, 2026, 2031, 2036 (%)
  • Figure 169 Europe Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 170 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Gene Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 171 Europe Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 172 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Viral Vector Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 173 Europe Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 174 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Non-Viral Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 175 Europe Cell & Gene Therapy Manufacturing Market Forecast by Source of Cells, 2026-2036 (US$ Million, AGR %)
  • Figure 176 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Source of Cells, 2026, 2031, 2036 (%)
  • Figure 177 Europe Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 178 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Scale of Operation, 2026, 2031, 2036 (%)
  • Figure 179 Europe Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR %)
  • Figure 180 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Type of Manufacturer, 2026, 2031, 2036 (%)
  • Figure 181 Europe Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR %)
  • Figure 182 Europe Cell & Gene Therapy Manufacturing Market Share Forecast by Workflow, 2026, 2031, 2036 (%)
  • Figure 183 Germany Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 184 UK Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 185 France Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 186 Italy Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 187 Spain Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 188 Russia Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 189 Rest of Europe Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 190 Asia Pacific Cell & Gene Therapy Manufacturing Market Attractiveness Index
  • Figure 191 Asia Pacific Cell & Gene Therapy Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • Figure 192 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 193 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 194 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Therapy Type, 2026-2036 (US$ Million, AGR %)
  • Figure 195 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Therapy Type, 2026, 2031, 2036 (%)
  • Figure 196 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 197 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Cell Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 198 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapies, 2026-2036 (US$ Million, AGR %)
  • Figure 199 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Immune Cell Therapies, 2026, 2031, 2036 (%)
  • Figure 200 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapies, 2026-2036 (US$ Million, AGR %)
  • Figure 201 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Stem Cell Therapies, 2026, 2031, 2036 (%)
  • Figure 202 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 203 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Gene Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 204 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 205 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Viral Vector Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 206 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 207 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Non-Viral Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 208 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Source of Cells, 2026-2036 (US$ Million, AGR %)
  • Figure 209 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Source of Cells, 2026, 2031, 2036 (%)
  • Figure 210 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 211 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Scale of Operation, 2026, 2031, 2036 (%)
  • Figure 212 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR %)
  • Figure 213 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Type of Manufacturer, 2026, 2031, 2036 (%)
  • Figure 214 Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR %)
  • Figure 215 Asia Pacific Cell & Gene Therapy Manufacturing Market Share Forecast by Workflow, 2026, 2031, 2036 (%)
  • Figure 216 Japan Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 217 China Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 218 India Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 219 Australia Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 220 South Korea Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 221 Rest of Asia Pacific Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 222 Latin America Cell & Gene Therapy Manufacturing Market Attractiveness Index
  • Figure 223 Latin America Cell & Gene Therapy Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • Figure 224 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 225 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 226 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Therapy Type, 2026-2036 (US$ Million, AGR %)
  • Figure 227 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Therapy Type, 2026, 2031, 2036 (%)
  • Figure 228 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 229 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Cell Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 230 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapies, 2026-2036 (US$ Million, AGR %)
  • Figure 231 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Immune Cell Therapies, 2026, 2031, 2036 (%)
  • Figure 232 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapies, 2026-2036 (US$ Million, AGR %)
  • Figure 233 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Stem Cell Therapies, 2026, 2031, 2036 (%)
  • Figure 234 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 235 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Gene Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 236 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 237 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Viral Vector Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 238 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 239 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Non-Viral Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 240 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Source of Cells, 2026-2036 (US$ Million, AGR %)
  • Figure 241 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Source of Cells, 2026, 2031, 2036 (%)
  • Figure 242 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 243 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Scale of Operation, 2026, 2031, 2036 (%)
  • Figure 244 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR %)
  • Figure 245 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Type of Manufacturer, 2026, 2031, 2036 (%)

145.2

  • Figure 246 Latin America Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR %)
  • Figure 247 Latin America Cell & Gene Therapy Manufacturing Market Share Forecast by Workflow, 2026, 2031, 2036 (%)
  • Figure 248 Brazil Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 249 Mexico Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 250 Argentina Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 251 Rest of Latin America Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 252 MEA Cell & Gene Therapy Manufacturing Market Attractiveness Index
  • Figure 253 MEA Cell & Gene Therapy Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • Figure 254 MEA Cell & Gene Therapy Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 255 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 256 MEA Cell & Gene Therapy Manufacturing Market Forecast by Therapy Type, 2026-2036 (US$ Million, AGR %)
  • Figure 257 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Therapy Type, 2026, 2031, 2036 (%)
  • Figure 258 MEA Cell & Gene Therapy Manufacturing Market Forecast by Cell Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 259 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Cell Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 260 MEA Cell & Gene Therapy Manufacturing Market Forecast by Immune Cell Therapies, 2026-2036 (US$ Million, AGR %)
  • Figure 261 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Immune Cell Therapies, 2026, 2031, 2036 (%)
  • Figure 262 MEA Cell & Gene Therapy Manufacturing Market Forecast by Stem Cell Therapies, 2026-2036 (US$ Million, AGR %)
  • Figure 263 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Stem Cell Therapies, 2026, 2031, 2036 (%)
  • Figure 264 MEA Cell & Gene Therapy Manufacturing Market Forecast by Gene Therapy Manufacturing, 2026-2036 (US$ Million, AGR %)
  • Figure 265 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Gene Therapy Manufacturing, 2026, 2031, 2036 (%)
  • Figure 266 MEA Cell & Gene Therapy Manufacturing Market Forecast by Viral Vector Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 267 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Viral Vector Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 268 MEA Cell & Gene Therapy Manufacturing Market Forecast by Non-Viral Gene Therapy, 2026-2036 (US$ Million, AGR %)
  • Figure 269 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Non-Viral Gene Therapy, 2026, 2031, 2036 (%)
  • Figure 270 MEA Cell & Gene Therapy Manufacturing Market Forecast by Source of Cells, 2026-2036 (US$ Million, AGR %)
  • Figure 271 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Source of Cells, 2026, 2031, 2036 (%)
  • Figure 272 MEA Cell & Gene Therapy Manufacturing Market Forecast by Scale of Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 273 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Scale of Operation, 2026, 2031, 2036 (%)
  • Figure 274 MEA Cell & Gene Therapy Manufacturing Market Forecast by Type of Manufacturer, 2026-2036 (US$ Million, AGR %)
  • Figure 275 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Type of Manufacturer, 2026, 2031, 2036 (%)
  • Figure 276 MEA Cell & Gene Therapy Manufacturing Market Forecast by Workflow, 2026-2036 (US$ Million, AGR %)
  • Figure 277 MEA Cell & Gene Therapy Manufacturing Market Share Forecast by Workflow, 2026, 2031, 2036 (%)
  • Figure 278 GCC Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 279 South Africa Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 280 Egypt Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 281 Rest of MEA Cell & Gene Therapy Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 282 Cell & Gene Therapy Manufacturing Market: Company Share/Ranking, 2025
  • Figure 283 Boehringer Ingelheim International GmbH: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 284 Boehringer Ingelheim International GmbH: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 285 Boehringer Ingelheim International GmbH: Regional Market Shares, 2025
  • Figure 286 Boehringer Ingelheim International GmbH: Business Segment Market Shares, 2025
  • Figure 287 Novo Holdings: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 288 Charles River Laboratories International Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 289 Charles River Laboratories International Inc.: Regional Market Shares, 2025
  • Figure 290 Charles River Laboratories International Inc.: Business Segment Market Shares, 2025
  • Figure 291 F. Hoffmann-La Roche Ltd.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 292 F. Hoffmann-La Roche Ltd.: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 293 F. Hoffmann-La Roche Ltd.: Regional Market Shares, 2025
  • Figure 294 F. Hoffmann-La Roche Ltd.: Business Segment Market Shares, 2025
  • Figure 295 Fujifilm Holdings Corporation: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 296 Fujifilm Holdings Corporation: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 297 Fujifilm Holdings Corporation: Regional Market Shares, 2025
  • Figure 298 Fujifilm Holdings Corporation: Business Segment Market Shares, 2025
  • Figure 299 Lonza: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 300 Lonza: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 301 Lonza: Regional Market Shares, 2025
  • Figure 302 Lonza: Business Segment Market Shares, 2025
  • Figure 303 Merck KGaA: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 304 Merck KGaA: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 305 Merck KGaA: Regional Market Shares, 2025
  • Figure 306 Merck KGaA: Business Segment Market Shares, 2025
  • Figure 307 Novartis AG: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 308 Novartis AG: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 309 Novartis AG: Regional Market Shares, 2025
  • Figure 310 Novartis AG: Business Segment Market Shares, 2025
  • Figure 311 OxFord Biomedica PLC: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 312 OxFord Biomedica PLC: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 313 OxFord Biomedica PLC: Regional Market Shares, 2025
  • Figure 314 OxFord Biomedica PLC: Business Segment Market Shares, 2025
  • Figure 315 Resonac Corporation: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 316 Resonac Corporation: Business Segment Market Shares, 2025
  • Figure 317 Samsung Epis Holdings: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 318 Takara Bio, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 319 Takara Bio, Inc.: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 320 Takara Bio, Inc.: Business Segment Market Shares, 2025
  • Figure 321 Thermo Fisher Scientific: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 322 Thermo Fisher Scientific: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 323 Thermo Fisher Scientific Inc.: Regional Market Shares, 2024
  • Figure 324 Thermo Fisher Scientific: Business Segment Market Shares, 2025
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!